Mei-Rong Ke
Overview
Explore the profile of Mei-Rong Ke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dharmaratne P, Wang B, Wong R, Chan B, Lau K, Ke M, et al.
Emerg Microbes Infect
. 2020 Jul;
9(1):1628-1637.
PMID: 32619386
Antimicrobial photodynamic therapy (aPDT) is an innovative approach to combat multi-drug resistant bacteria. It is known that cationic Zn(II) phthalocyanines (ZnPc) are effective in mediating aPDT against methicillin-resistant (MRSA). Here...
12.
Li D, Hu Q, Wang X, Li X, Hu J, Zheng B, et al.
Bioorg Med Chem Lett
. 2020 Apr;
30(12):127164.
PMID: 32291134
To develop a highly efficient photosensitizer for photodynamic therapy (PDT), we have designed and synthesized a phthalocyanine-lactose conjugate (Pc-Lac) through axial modification of silicon(IV) phthalocyanine with lactose moieties. With the...
13.
Wan D, Ma X, Lin C, Zhu D, Li X, Zheng B, et al.
Bioconjug Chem
. 2020 Apr;
31(5):1438-1448.
PMID: 32255337
Fabrication of a multifunctional near-infrared (NIR) theranostic nanoplatform has attracted increasing attention. Indocyanine green (ICG), a clinic-approved NIR fluorescence-imaging agent, is an excellent photothermal agent candidate. However, the stability and...
14.
Li D, Wang X, Yang L, Li S, Hu Q, Li X, et al.
ACS Appl Mater Interfaces
. 2019 Sep;
11(40):36435-36443.
PMID: 31525892
Self-assembled phototheranostic nanomaterials used for photodynamic therapy (PDT) have attracted increasing attention owing to their several advantages. Herein, we developed a novel strategy for size-tunable self-assembled nanophotosensitizers for PDT through...
15.
Lin A, Li S, Xu C, Li X, Zheng B, Gu J, et al.
Biomater Sci
. 2018 Nov;
7(1):211-219.
PMID: 30426113
Development of a photosensitizer that can achieve tumor specificity, improve therapeutic efficacy, and reduce side effects remains a challenge for photodynamic therapy (PDT). In this work, a pH-sensitive activatable nanophotosensitizer...
16.
Zheng B, Yang X, Zhao Y, Zheng Q, Ke M, Lin T, et al.
Eur J Med Chem
. 2018 Jun;
155:24-33.
PMID: 29852329
A series of novel symmetric or unsymmetric silicon (IV) phthalocyanines axially substituted with cyclic Arg-Gly-Asp (cRGD) ligands through different ethylene glycol chains have been synthesized by a facile and mild...
17.
Ren X, Hao X, Li H, Ke M, Zheng B, Huang J
Drug Discov Today
. 2018 May;
23(10):1791-1800.
PMID: 29803933
In recent years, photodynamic therapy has been applied in cancer treatment because of its high selectivity and marginal invasion properties. However, the excitation light used has limited ability to penetrate...
18.
Li X, Peng X, Zheng B, Tang J, Zhao Y, Zheng B, et al.
Chem Sci
. 2018 Apr;
9(8):2098-2104.
PMID: 29675251
Phthalocyanine (Pc) molecules exhibit high extinction coefficients in near-infrared region, rendering them well-suited for phototherapies, but most of their applications are limited to the field of photodynamic therapy (PDT). Herein,...
19.
Li X, Yu S, Lee D, Kim G, Lee B, Cho Y, et al.
ACS Nano
. 2017 Dec;
12(1):681-688.
PMID: 29232105
Supramolecular chemistry provides a "bottom-up" method to fabricate nanostructures for biomedical applications. Herein, we report a facile strategy to directly assemble a phthalocyanine photosensitizer (PcS) with an anticancer drug mitoxantrone...
20.
Li X, Zheng B, Ke M, Zhang Y, Huang J, Yoon J
Theranostics
. 2017 Aug;
7(10):2746-2756.
PMID: 28819460
A major challenge in photodynamic therapy (PDT) is the development of new tumor-targeting photosensitizers. The tumor-specific activation is considered to be an effective strategy for designing these photosensitizers. Herein, we...